CEPI’s call for new individuals to join its Scientific Advisory Committee, or SAC—an external expert group providing guidance and recommendations to CEPI on R&D programmes… Read More »CEPI calls for experts to join its Scientific Advisory Committee
Results showing that the combination of enfortumab vedotin and pembrolizumab produced “dramatic improvements” in survival were greeted with cheers. Patients with muscle-invasive bladder cancer (MIBC)… Read More »Loud Applause Greets Survival Data at ESMO 2025 That Mark “New Era” for Bladder Cancer Care
Ghent, Belgium – 1–2 October 2025 — The 10th edition of Immunity for Health, the flagship event of Flanders Vaccine, marked both a celebration and… Read More »Flanders Vaccine Marks 10th Anniversary of ‘Immunity for Health’ with a New Identity and Global Vision
Review article The global surge in antimicrobial resistance presents a critical threat to public health, emphasizing the urgent need for the development of new and… Read More »Challenges and opportunities in mRNA vaccine development against bacteria
GSK today announced that the US Food and Drug Administration (FDA) has approved a prefilled syringe presentation of Shingrix (GSK’s Recombinant Zoster Vaccine or RZV) for the… Read More »FDA approves Shingrix in a prefilled syringe presentation
Immunity for health is proud to share that Prof. Pierre Van Damme, co-founder and long-standing Vice-Chairman of our Board of Directors, has been awarded the… Read More »Prof. Pierre Van Damme receives honorary title of Baron
Immunity for health is pleased to welcome Dieter Vancraeynest as a new member of its Board of Directors. Dieter joins the Board as a representative… Read More »New member of the Board of Directors: Dieter Vancraeynest, Zoetis, joins Immunity for health
